Engineering human PEG10-based nanoparticles for RNA self-packaging, delivery and cancer therapy.

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Therapy

Background:

• PEG10 protein forms nanoparticles, but production is costly and its therapeutic potential is unexplored.
• Existing methods for nanoparticle production require expensive transfection, limiting their clinical application.

Purpose of the Study:

• To develop an improved, cost-effective platform of human PEG10-based nanoparticles (PBNPs) for mRNA self-packaging and cancer therapy.
• To enhance PBNP production efficiency and mRNA delivery capabilities for various cancer types.

Main Methods:

• Engineered a novel process to improve PBNP production yield by 11.3-fold and reduce costs.
• Demonstrated PBNP capability to self-package large mRNA molecules (≥7336 nucleotides) and assessed their stability over 7 months.
• Modified PBNP surface to enhance mRNA delivery efficiency to cancer cells, particularly colon cancer cells.

Main Results:

• Achieved significant improvement in PBNP production efficiency and cost reduction.
• Confirmed PBNPs can package large mRNA and maintain stability for extended periods.
• Engineered PBNPs demonstrated high mRNA delivery efficiency (≈71% in colon cancer cells) and elicited T cell responses in vitro.
• In vivo studies showed synergistic anti-cancer effects when PBNPs delivering immunotherapeutic mRNA were co-administered with chemodrugs.

Conclusions:

• Developed a cost-effective and efficient PBNP platform for mRNA delivery in cancer therapy.
• Demonstrated the potential of PBNPs for delivering immunotherapeutic mRNA cocktails, enhancing anti-cancer efficacy through synergistic immune responses.